Clinical studies have revealed direct correlations between reduced serum FGF21 levels and the development of various CVDs, such as myocardial ischemia, CAD, cardiac hypertrophy, atherosclerosis, and diabetic cardiomyopathy, supporting the protective function of endogenous FGF21 against CVDs. This evidence concerns the gene FGF21 and atherosclerosis.